Poly-ADP-polymerase (PARP) inhibitors have favorable therapeutic effects on BRCA1-mutated breast cancer, and preclinical studies have shown that the PARP inhibitor olaparib significantly reduced the proportion of BCSCs, suggesting that it acts against these cells [68]. The gene discussed is BRCA1; the disease is breast cancer.